- NCIt
- C40283
Loading cancer entity…
Loading cancer entity…
Clinical trials
57 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03074513 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | active not recruiting | Phase 2 | 133 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07804966 | Sac-TMT in Vaginal and Vulvar Cancers(ARCANA) | not yet recruiting | Phase 2 | 48 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT02978625 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | active not recruiting | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07679841 | Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma Patients(COLOMBE) | not yet recruiting | Phase 1 / Phase 2 | 50 | Centre Leon BerardOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | recruiting | Phase 1 / Phase 2 | 15 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05686226 | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | recruiting | Phase 2 | 20 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04430699 | Cisplatin+Pembrolizumab+RT in Vulvar Cancer | active not recruiting | Phase 2 | 24 | Massachusetts General HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03260023 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | active not recruiting | Phase 1 / Phase 2 | 143 | TransgeneINDUSTRY | 3 | Feb 5, 2026 | clinicaltrials |
| NCT06075264 | Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)(ART-VIN IIB) | recruiting | Phase 2 | 27 | Frantz Viral Therapeutics, LLCINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT05104099 | Evaluation of New Diagnostic Tool Using Fluorescence to Detect High-grade Vulvar Intraepithelial Neoplasia(PhotodiVIN) | completed | Phase 2 | 17 | Institut de Cancérologie de LorraineOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT03267680 | IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3 | terminated | Phase 2 | 10 | University of Southern CaliforniaOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT05905315 | Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC(VULCANIZE-II) | recruiting | Phase 2 | 98 | The Netherlands Cancer InstituteOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT03180684 | Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) | completed | Phase 2 | 33 | Inovio PharmaceuticalsINDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT04161664 | Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy(CRAVAT) | recruiting | Phase 2 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT01595061 | Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva | unknown | Phase 2 | 57 | Gynecologic Oncology GroupNETWORK | 1 | Dec 29, 2021 | clinicaltrials |
| NCT03937791 | Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Apr 13, 2021 | clinicaltrials |
| NCT00068406 | Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva | completed | Phase 2 | 61 | Gynecologic Oncology GroupNETWORK | 1 | Nov 20, 2017 | clinicaltrials |
| NCT01986725 | The Impact of the "WOMAN-PRO II Program" on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence(WOMAN-PROII) | completed | Phase 2 | 45 | St.Gallen University of Applied SciencesOTHER | 1 | Jan 7, 2016 | clinicaltrials |
Data updated 15 days agoSource updated Sep 14, 2026source: clinicaltrials